GlaxoSmithKline's COVID-19 antibody delivers as Nucala, Trelegy eclipse £1B landmark

GlaxoSmithKline ended 2021 on a relatively high note saleswise, with its COVID-19 antibody therapy delivering a nice contribution and two key meds surpassing the £1 billion annual revenue mark for the first time.

Xevudy, the Vir Biotechnology-partnered COVID therapy, delivered £828 million ($1.12 billion) sales in the fourth quarter. Out of the 25% growth GSK’s drug business enjoyed at constant currencies during the three-month period, the antibody contributed nearly 20 percentage points, the company said.